Cardinal Health (CAH)
(Delayed Data from NYSE)
$98.51 USD
-0.29 (-0.29%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $98.50 -0.01 (-0.01%) 5:52 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.51 USD
-0.29 (-0.29%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $98.50 -0.01 (-0.01%) 5:52 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Zacks News
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DVP
Here's Why You Should Hold on to Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Cardinal (CAH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Top Ranked Income Stocks to Buy for January 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 6th.
Top Ranked Income Stocks to Buy for January 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 2nd.
Here's Why You Should Hold on to Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVP
Top Ranked Income Stocks to Buy for December 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 27th.
Top Ranked Income Stocks to Buy for December 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 20th.
Top Ranked Income Stocks to Buy for December 19th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 19th.
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardinal (CAH) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVP
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.